Latest Commercialisation News

Sparc Hydrogen, in partnership with the University of Adelaide, has won a $2.75 million Australian Government grant to advance its pioneering green hydrogen pilot plant. This funding underscores the commercial promise of its novel photocatalytic water splitting technology.

Metallium Ltd, formerly MTM Critical Metals, has upgraded its U.S. listing to the OTCQX Best Market, enhancing investor access and aligning with its expanding U.S. operations including a new Texas commercial site.

Acrux Limited has secured a further $0.46 million advance on its FY25 R&D Tax Incentive, bringing total advances to $2.19 million and supporting its pharmaceutical product development and working capital needs.

BCAL Diagnostics has secured a strategic partnership with Cancer Care Associates to fast-track the clinical adoption and revenue generation of its innovative BREASTEST plus™ breast cancer blood test starting FY2026.

Gold Hydrogen has attracted a $14.5 million strategic investment from global energy leaders Toyota, Mitsubishi Gas Chemical, and ENEOS Xplora, following promising drilling results in South Australia. The funds will accelerate exploration and commercialisation of natural hydrogen and helium resources.

Proteomics International has secured a dedicated US reimbursement code for its next-generation PromarkerD test, a key step towards broader adoption in diabetic kidney disease diagnostics.

First Graphene Limited is progressing two major projects in hydrogen storage and aerospace 3D printing, backed by multi-million-dollar UK grants to commercialise graphene-enhanced technologies.

Lithium Universe has completed legal due diligence on its acquisition of New Age Minerals, securing exclusive rights to a patented solar panel recycling technology. This move positions the company to expand its sustainable footprint in the lithium supply chain.

Yojee Limited has successfully raised $5.4 million through an oversubscribed placement, fueling development of its MOSAIC freight forwarding platform and expansion across the Asia Pacific region.

Vitasora Health has secured approximately A$11 million in capital to accelerate its expansion in the US remote patient monitoring market, highlighted by an upgraded contract with TPAC covering 15,000 patients. The company targets a USD 18 million annual recurring revenue run-rate by late 2026.

Neurizon Therapeutics has inked a pivotal global licensing deal with Elanco Animal Health, unlocking critical intellectual property and data to accelerate the development and commercialisation of its lead drug candidate NUZ-001 for neurodegenerative diseases including ALS.

Pancontinental Energy’s latest technical update reveals promising hydrocarbon potential in the PEL 87 offshore Namibia project, supported by advanced seismic and basin modelling studies. These findings set the stage for revised resource estimates later this month.